ID   IKZF1_HUMAN             Reviewed;         519 AA.
AC   Q13422; A4D260; B4E0Z1; D3DVM5; O00598; Q53XL2; Q69BM4; Q8WVA3;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JAN-2026, entry version 223.
DE   RecName: Full=DNA-binding protein Ikaros;
DE   AltName: Full=Ikaros family zinc finger protein 1;
DE   AltName: Full=Lymphoid transcription factor LyF-1;
GN   Name=IKZF1; Synonyms=IK1, IKAROS, LYF1, ZNFN1A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RC   TISSUE=Bone marrow;
RX   PubMed=8964602; DOI=10.1016/0165-2478(95)02479-4;
RA   Nietfeld W., Meyerhans A.;
RT   "Cloning and sequencing of hIk-1, a cDNA encoding a human homologue of
RT   mouse Ikaros/LyF-1.";
RL   Immunol. Lett. 49:139-141(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=8543809;
RA   Molnar A., Wu P., Largespada D.A., Vortkamp A., Scherer S., Copeland N.G.,
RA   Jenkins N.A., Bruns G., Georgopoulos K.;
RT   "The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA
RT   binding proteins, highly conserved in human and mouse.";
RL   J. Immunol. 156:585-592(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM IKX).
RA   Sanchez-Tapia E.M., Rodriguez R.E., Gonzalez-Sarmiento R.;
RT   "Molecular misreading is involved in generation of Ikaros diversity.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IK2).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IK7).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM IK7).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   IDENTIFICATION IN THE NURD COMPLEX, INTERACTION WITH SMARCA4 AND CHD4, AND
RP   FUNCTION.
RX   PubMed=10204490; DOI=10.1016/s1074-7613(00)80034-5;
RA   Kim J., Sif S., Jones B., Jackson A., Koipally J., Heller E., Winandy S.,
RA   Viel A., Sawyer A., Ikeda T., Kingston R., Georgopoulos K.;
RT   "Ikaros DNA-binding proteins direct formation of chromatin remodeling
RT   complexes in lymphocytes.";
RL   Immunity 10:345-355(1999).
RN   [11]
RP   INVOLVEMENT IN B-CELL NON-HODGKIN LYMPHOMA, AND CHROMOSOMAL TRANSLOCATION
RP   WITH BCL6.
RX   PubMed=10753856;
RA   Hosokawa Y., Maeda Y., Ichinohasama R., Miura I., Taniwaki M., Seto M.;
RT   "The Ikaros gene, a central regulator of lymphoid differentiation, fuses to
RT   the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient
RT   with diffuse large B-cell lymphoma.";
RL   Blood 95:2719-2721(2000).
RN   [12]
RP   INTERACTION WITH IKZF4 AND IKZF5.
RX   PubMed=10978333; DOI=10.1074/jbc.m005457200;
RA   Perdomo J., Holmes M., Chong B., Crossley M.;
RT   "Eos and pegasus, two members of the Ikaros family of proteins with
RT   distinct DNA binding activities.";
RL   J. Biol. Chem. 275:38347-38354(2000).
RN   [13]
RP   FUNCTION, ALTERNATIVE SPLICING, SUBCELLULAR LOCATION, AND SUBUNIT.
RX   PubMed=17135265; DOI=10.1074/jbc.m605627200;
RA   Ronni T., Payne K.J., Ho S., Bradley M.N., Dorsam G., Dovat S.;
RT   "Human Ikaros function in activated T cells is regulated by coordinated
RT   expression of its largest isoforms.";
RL   J. Biol. Chem. 282:2538-2547(2007).
RN   [14]
RP   FUNCTION, AND ALTERNATIVE SPLICING.
RX   PubMed=17934067; DOI=10.1182/blood-2007-07-098202;
RA   Dijon M., Bardin F., Murati A., Batoz M., Chabannon C., Tonnelle C.;
RT   "The role of Ikaros in human erythroid differentiation.";
RL   Blood 111:1138-1146(2008).
RN   [15]
RP   FUNCTION IN GAMMA SATELLITE DNA-BINDING.
RX   PubMed=19141594; DOI=10.1101/gr.086496.108;
RA   Kim J.-H., Ebersole T., Kouprina N., Noskov V.N., Ohzeki J.-I.,
RA   Masumoto H., Mravinac B., Sullivan B.A., Pavlicek A., Dovat S., Pack S.D.,
RA   Kwon Y.-W., Flanagan P.T., Loukinov D., Lobanenkov V., Larionov V.;
RT   "Human gamma-satellite DNA maintains open chromatin structure and protects
RT   a transgene from epigenetic silencing.";
RL   Genome Res. 19:533-544(2009).
RN   [16]
RP   INVOLVEMENT IN ACUTE LYMPHOBLASIC LEUKEMIA.
RX   PubMed=19129520; DOI=10.1056/nejmoa0808253;
RA   Mullighan C.G., Su X., Zhang J., Radtke I., Phillips L.A., Miller C.B.,
RA   Ma J., Liu W., Cheng C., Schulman B.A., Harvey R.C., Chen I.-M.,
RA   Clifford R.J., Carroll W.L., Reaman G., Bowman W.P., Devidas M.,
RA   Gerhard D.S., Yang W., Relling M.V., Shurtleff S.A., Campana D.,
RA   Borowitz M.J., Pui C.H., Smith M., Hunger S.P., Willman C.L., Downing J.R.;
RT   "Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.";
RL   N. Engl. J. Med. 360:470-480(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63; SER-258; SER-361 AND
RP   SER-364, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   FUNCTION IN DNA-BINDING, SUBCELLULAR LOCATION, PHOSPHORYLATION, AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=22106042; DOI=10.1002/pbc.23406;
RA   Li Z., Song C., Ouyang H., Lai L., Payne K.J., Dovat S.;
RT   "Cell cycle-specific function of Ikaros in human leukemia.";
RL   Pediatr. Blood Cancer 59:69-76(2012).
RN   [20]
RP   PHOSPHORYLATION AT SER-361 AND SER-364 BY SYK, AND SUBCELLULAR LOCATION.
RX   PubMed=23071339; DOI=10.1073/pnas.1209828109;
RA   Uckun F.M., Ma H., Zhang J., Ozer Z., Dovat S., Mao C., Ishkhanian R.,
RA   Goodman P., Qazi S.;
RT   "Serine phosphorylation by SYK is critical for nuclear localization and
RT   transcription factor function of Ikaros.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:18072-18077(2012).
RN   [21]
RP   INVOLVEMENT IN CVID13, VARIANT CVID13 CYS-210, CHARACTERIZATION OF VARIANT
RP   CVID13 CYS-210, AND SUBCELLULAR LOCATION.
RX   PubMed=21548011; DOI=10.1002/pbc.23160;
RA   Goldman F.D., Gurel Z., Al-Zubeidi D., Fried A.J., Icardi M., Song C.,
RA   Dovat S.;
RT   "Congenital pancytopenia and absence of B lymphocytes in a neonate with a
RT   mutation in the Ikaros gene.";
RL   Pediatr. Blood Cancer 58:591-597(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-63; SER-261; SER-289;
RP   SER-298; SER-364; SER-368; SER-427 AND SER-445, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-445, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   VARIANTS CVID13 GLN-162; LEU-162; ARG-167 AND GLN-184, CHARACTERIZATION OF
RP   VARIANTS CVID13 GLN-162; LEU-162; ARG-167; GLN-184 AND CYS-210, AND
RP   MUTAGENESIS OF ASN-159 AND HIS-191.
RX   PubMed=26981933; DOI=10.1056/nejmoa1512234;
RA   Kuehn H.S., Boisson B., Cunningham-Rundles C., Reichenbach J.,
RA   Stray-Pedersen A., Gelfand E.W., Maffucci P., Pierce K.R., Abbott J.K.,
RA   Voelkerding K.V., South S.T., Augustine N.H., Bush J.S., Dolen W.K.,
RA   Wray B.B., Itan Y., Cobat A., Sorte H.S., Ganesan S., Prader S.,
RA   Martins T.B., Lawrence M.G., Orange J.S., Calvo K.R., Niemela J.E.,
RA   Casanova J.L., Fleisher T.A., Hill H.R., Kumanovics A., Conley M.E.,
RA   Rosenzweig S.D.;
RT   "Loss of B Cells in Patients with Heterozygous Mutations in IKAROS.";
RL   N. Engl. J. Med. 374:1032-1043(2016).
CC   -!- FUNCTION: Transcription regulator of hematopoietic cell differentiation
CC       (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265,
CC       PubMed:19141594). Plays a role in the development of lymphocytes,
CC       B- and T-cells. Binds and activates the enhancer (delta-A element) of
CC       the CD3-delta gene. Repressor of the TDT (fikzfterminal
CC       deoxynucleotidyltransferase) gene during thymocyte differentiation.
CC       Regulates transcription through association with both HDAC-dependent
CC       and HDAC-independent complexes. Targets the 2 chromatin-remodeling
CC       complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex),
CC       to the beta-globin locus in adult erythrocytes. Increases normal
CC       apoptosis in adult erythroid cells. Confers early temporal competence
CC       to retinal progenitor cells (RPCs) (By similarity). Function is
CC       isoform-specific and is modulated by dominant-negative inactive
CC       isoforms (PubMed:17135265, PubMed:17934067).
CC       {ECO:0000250|UniProtKB:Q03267, ECO:0000269|PubMed:10204490,
CC       ECO:0000269|PubMed:17135265, ECO:0000269|PubMed:17934067,
CC       ECO:0000269|PubMed:19141594}.
CC   -!- SUBUNIT: Heterodimer formed by the various isoforms; this modulates
CC       transcription regulator activity (PubMed:17135265, PubMed:17934067).
CC       Heterodimer with other IKAROS family members. Interacts with IKZF4 AND
CC       IKZF5 (PubMed:10978333). Component of the chromatin-remodeling NuRD
CC       repressor complex which includes at least HDAC1, HDAC2, RBBP4, RBBP7,
CC       IKZF1, MTA2, MBD2, MBD3, MTA1L1, CHD3 and CHD4. Interacts directly with
CC       the CHD4 component of the NuRD complex. Interacts directly with
CC       SMARCA4; the interaction associates IKFZ1 with the BAF complex
CC       (PubMed:10204490). Interacts with SUMO1; the interaction sumoylates
CC       IKAROS, promoted by PIAS2 and PIAS3. Interacts with PIAS2 (isoform
CC       alpha); the interaction promotes sumoylation and reduces transcription
CC       repression. Interacts, to a lesser extent, with PIAS3. Interacts with
CC       PPP1CC; the interaction targets PPP1CC to pericentromeric
CC       heterochromatin, dephosphorylates IKAROS, stabilizes it and prevents it
CC       from degradation. Interacts with IKZF3 (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:10204490, ECO:0000269|PubMed:10978333,
CC       ECO:0000305|PubMed:17135265, ECO:0000305|PubMed:17934067}.
CC   -!- INTERACTION:
CC       Q13422; Q8WTP8: AEN; NbExp=3; IntAct=EBI-745305, EBI-8637627;
CC       Q13422; Q9NX04: AIRIM; NbExp=3; IntAct=EBI-745305, EBI-8643161;
CC       Q13422; Q96Q83: ALKBH3; NbExp=5; IntAct=EBI-745305, EBI-6658697;
CC       Q13422; Q9BXS5: AP1M1; NbExp=3; IntAct=EBI-745305, EBI-541426;
CC       Q13422; Q9H6L4: ARMC7; NbExp=3; IntAct=EBI-745305, EBI-742909;
CC       Q13422; Q7L5A3: ATOSB; NbExp=6; IntAct=EBI-745305, EBI-745689;
CC       Q13422; Q13895: BYSL; NbExp=5; IntAct=EBI-745305, EBI-358049;
CC       Q13422; Q8IYL3: C1orf174; NbExp=4; IntAct=EBI-745305, EBI-715898;
CC       Q13422; Q9H7E9: C8orf33; NbExp=3; IntAct=EBI-745305, EBI-715389;
CC       Q13422; Q9HC52: CBX8; NbExp=3; IntAct=EBI-745305, EBI-712912;
CC       Q13422; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-745305, EBI-10181988;
CC       Q13422; P61024: CKS1B; NbExp=3; IntAct=EBI-745305, EBI-456371;
CC       Q13422; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-745305, EBI-10171858;
CC       Q13422; P56545: CTBP2; NbExp=7; IntAct=EBI-745305, EBI-741533;
CC       Q13422; P56545-3: CTBP2; NbExp=3; IntAct=EBI-745305, EBI-10171902;
CC       Q13422; O43602: DCX; NbExp=4; IntAct=EBI-745305, EBI-8646694;
CC       Q13422; P26196: DDX6; NbExp=4; IntAct=EBI-745305, EBI-351257;
CC       Q13422; Q92630: DYRK2; NbExp=3; IntAct=EBI-745305, EBI-749432;
CC       Q13422; Q3B820: FAM161A; NbExp=3; IntAct=EBI-745305, EBI-719941;
CC       Q13422; Q9Y247: FAM50B; NbExp=4; IntAct=EBI-745305, EBI-742802;
CC       Q13422; P61328: FGF12; NbExp=3; IntAct=EBI-745305, EBI-6657662;
CC       Q13422; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-745305, EBI-741729;
CC       Q13422; O76003: GLRX3; NbExp=3; IntAct=EBI-745305, EBI-374781;
CC       Q13422; Q8NEA9: GMCL2; NbExp=4; IntAct=EBI-745305, EBI-8641829;
CC       Q13422; Q9H1K1: ISCU; NbExp=3; IntAct=EBI-745305, EBI-1047335;
CC       Q13422; Q8TAP4: LMO3; NbExp=3; IntAct=EBI-745305, EBI-742259;
CC       Q13422; Q9Y4Z0: LSM4; NbExp=3; IntAct=EBI-745305, EBI-372521;
CC       Q13422; Q9UI95: MAD2L2; NbExp=3; IntAct=EBI-745305, EBI-77889;
CC       Q13422; Q96EZ8: MCRS1; NbExp=4; IntAct=EBI-745305, EBI-348259;
CC       Q13422; Q9UBU8: MORF4L1; NbExp=3; IntAct=EBI-745305, EBI-399246;
CC       Q13422; Q15014: MORF4L2; NbExp=3; IntAct=EBI-745305, EBI-399257;
CC       Q13422; Q13330: MTA1; NbExp=5; IntAct=EBI-745305, EBI-714236;
CC       Q13422; Q9HC98: NEK6; NbExp=3; IntAct=EBI-745305, EBI-740364;
CC       Q13422; Q9BVI4: NOC4L; NbExp=3; IntAct=EBI-745305, EBI-395927;
CC       Q13422; Q13526: PIN1; NbExp=3; IntAct=EBI-745305, EBI-714158;
CC       Q13422; Q96T60: PNKP; NbExp=3; IntAct=EBI-745305, EBI-1045072;
CC       Q13422; O43741: PRKAB2; NbExp=3; IntAct=EBI-745305, EBI-1053424;
CC       Q13422; P25786: PSMA1; NbExp=3; IntAct=EBI-745305, EBI-359352;
CC       Q13422; P25789: PSMA4; NbExp=3; IntAct=EBI-745305, EBI-359310;
CC       Q13422; O75771: RAD51D; NbExp=5; IntAct=EBI-745305, EBI-1055693;
CC       Q13422; P57060: RWDD2B; NbExp=4; IntAct=EBI-745305, EBI-724442;
CC       Q13422; Q9BWG6: SCNM1; NbExp=3; IntAct=EBI-745305, EBI-748391;
CC       Q13422; O00560: SDCBP; NbExp=3; IntAct=EBI-745305, EBI-727004;
CC       Q13422; Q9H788: SH2D4A; NbExp=3; IntAct=EBI-745305, EBI-747035;
CC       Q13422; Q9NUL5: SHFL; NbExp=3; IntAct=EBI-745305, EBI-10313866;
CC       Q13422; P62306: SNRPF; NbExp=3; IntAct=EBI-745305, EBI-356900;
CC       Q13422; Q13573: SNW1; NbExp=3; IntAct=EBI-745305, EBI-632715;
CC       Q13422; Q9H0A9: SPATC1L; NbExp=3; IntAct=EBI-745305, EBI-372911;
CC       Q13422; Q9BSW7: SYT17; NbExp=3; IntAct=EBI-745305, EBI-745392;
CC       Q13422; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-745305, EBI-10180829;
CC       Q13422; Q15007: WTAP; NbExp=4; IntAct=EBI-745305, EBI-751647;
CC       Q13422; Q96NC0: ZMAT2; NbExp=3; IntAct=EBI-745305, EBI-2682299;
CC       Q13422; Q8TAU3: ZNF417; NbExp=3; IntAct=EBI-745305, EBI-740727;
CC       Q13422; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-745305, EBI-745520;
CC       Q13422; A8K932; NbExp=3; IntAct=EBI-745305, EBI-10174671;
CC       Q13422-7; Q9NX04: AIRIM; NbExp=3; IntAct=EBI-11522367, EBI-8643161;
CC       Q13422-7; A1A5B0: ANKRD36; NbExp=3; IntAct=EBI-11522367, EBI-14100900;
CC       Q13422-7; Q9BXS5: AP1M1; NbExp=3; IntAct=EBI-11522367, EBI-541426;
CC       Q13422-7; Q7L5A3: ATOSB; NbExp=3; IntAct=EBI-11522367, EBI-745689;
CC       Q13422-7; Q99728: BARD1; NbExp=3; IntAct=EBI-11522367, EBI-473181;
CC       Q13422-7; Q13895: BYSL; NbExp=3; IntAct=EBI-11522367, EBI-358049;
CC       Q13422-7; Q8IYL3: C1orf174; NbExp=3; IntAct=EBI-11522367, EBI-715898;
CC       Q13422-7; Q9H7E9: C8orf33; NbExp=3; IntAct=EBI-11522367, EBI-715389;
CC       Q13422-7; Q9HC52: CBX8; NbExp=3; IntAct=EBI-11522367, EBI-712912;
CC       Q13422-7; Q8N715: CCDC185; NbExp=3; IntAct=EBI-11522367, EBI-740814;
CC       Q13422-7; O00311: CDC7; NbExp=3; IntAct=EBI-11522367, EBI-374980;
CC       Q13422-7; Q8IVW4: CDKL3; NbExp=3; IntAct=EBI-11522367, EBI-3919850;
CC       Q13422-7; P61024: CKS1B; NbExp=3; IntAct=EBI-11522367, EBI-456371;
CC       Q13422-7; Q96SW2-2: CRBN; NbExp=2; IntAct=EBI-11522367, EBI-10693561;
CC       Q13422-7; Q13363-2: CTBP1; NbExp=5; IntAct=EBI-11522367, EBI-10171858;
CC       Q13422-7; P56545-3: CTBP2; NbExp=3; IntAct=EBI-11522367, EBI-10171902;
CC       Q13422-7; Q2TBE0: CWF19L2; NbExp=3; IntAct=EBI-11522367, EBI-5453285;
CC       Q13422-7; O43602-2: DCX; NbExp=3; IntAct=EBI-11522367, EBI-14148644;
CC       Q13422-7; P26196: DDX6; NbExp=3; IntAct=EBI-11522367, EBI-351257;
CC       Q13422-7; Q14192: FHL2; NbExp=3; IntAct=EBI-11522367, EBI-701903;
CC       Q13422-7; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-11522367, EBI-13213391;
CC       Q13422-7; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-11522367, EBI-11522367;
CC       Q13422-7; A0A0S2Z5S9: LHX4; NbExp=3; IntAct=EBI-11522367, EBI-16429099;
CC       Q13422-7; P25800: LMO1; NbExp=3; IntAct=EBI-11522367, EBI-8639312;
CC       Q13422-7; P25791-3: LMO2; NbExp=3; IntAct=EBI-11522367, EBI-11959475;
CC       Q13422-7; Q8TAP4-4: LMO3; NbExp=3; IntAct=EBI-11522367, EBI-11742507;
CC       Q13422-7; P61968: LMO4; NbExp=3; IntAct=EBI-11522367, EBI-2798728;
CC       Q13422-7; Q96A72: MAGOHB; NbExp=3; IntAct=EBI-11522367, EBI-746778;
CC       Q13422-7; Q9UPY8: MAPRE3; NbExp=3; IntAct=EBI-11522367, EBI-726739;
CC       Q13422-7; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-11522367, EBI-348259;
CC       Q13422-7; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-11522367, EBI-16439278;
CC       Q13422-7; P00540: MOS; NbExp=3; IntAct=EBI-11522367, EBI-1757866;
CC       Q13422-7; Q9Y5B8: NME7; NbExp=6; IntAct=EBI-11522367, EBI-744782;
CC       Q13422-7; O43809: NUDT21; NbExp=3; IntAct=EBI-11522367, EBI-355720;
CC       Q13422-7; O75928-2: PIAS2; NbExp=3; IntAct=EBI-11522367, EBI-348567;
CC       Q13422-7; Q13526: PIN1; NbExp=3; IntAct=EBI-11522367, EBI-714158;
CC       Q13422-7; Q96T60: PNKP; NbExp=3; IntAct=EBI-11522367, EBI-1045072;
CC       Q13422-7; O60437: PPL; NbExp=3; IntAct=EBI-11522367, EBI-368321;
CC       Q13422-7; P54646: PRKAA2; NbExp=3; IntAct=EBI-11522367, EBI-1383852;
CC       Q13422-7; Q99633: PRPF18; NbExp=3; IntAct=EBI-11522367, EBI-2798416;
CC       Q13422-7; P25789: PSMA4; NbExp=3; IntAct=EBI-11522367, EBI-359310;
CC       Q13422-7; P47897: QARS1; NbExp=3; IntAct=EBI-11522367, EBI-347462;
CC       Q13422-7; O75771: RAD51D; NbExp=3; IntAct=EBI-11522367, EBI-1055693;
CC       Q13422-7; Q6ZSC3: RBM43; NbExp=3; IntAct=EBI-11522367, EBI-2880658;
CC       Q13422-7; P78317: RNF4; NbExp=3; IntAct=EBI-11522367, EBI-2340927;
CC       Q13422-7; A0A0S2Z4G9: RNF6; NbExp=3; IntAct=EBI-11522367, EBI-16428950;
CC       Q13422-7; Q9BWG6: SCNM1; NbExp=3; IntAct=EBI-11522367, EBI-748391;
CC       Q13422-7; P09661: SNRPA1; NbExp=3; IntAct=EBI-11522367, EBI-876439;
CC       Q13422-7; P62306: SNRPF; NbExp=3; IntAct=EBI-11522367, EBI-356900;
CC       Q13422-7; Q15560: TCEA2; NbExp=3; IntAct=EBI-11522367, EBI-710310;
CC       Q13422-7; Q5T7W7: TSTD2; NbExp=3; IntAct=EBI-11522367, EBI-8994397;
CC       Q13422-7; P42681: TXK; NbExp=3; IntAct=EBI-11522367, EBI-7877438;
CC       Q13422-7; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-11522367, EBI-10180829;
CC       Q13422-7; Q15007: WTAP; NbExp=7; IntAct=EBI-11522367, EBI-751647;
CC       Q13422-7; Q8TAU3: ZNF417; NbExp=3; IntAct=EBI-11522367, EBI-740727;
CC       Q13422-7; Q9UK33: ZNF580; NbExp=3; IntAct=EBI-11522367, EBI-746277;
CC       Q13422-7; Q96SQ5: ZNF587; NbExp=3; IntAct=EBI-11522367, EBI-6427977;
CC       Q13422-7; Q03233: ADD37; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-27402;
CC       Q13422-7; Q06671: ATG23; Xeno; NbExp=4; IntAct=EBI-11522367, EBI-3685534;
CC       Q13422-7; P39724: BOL3; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-2343154;
CC       Q13422-7; P32562: CDC5; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-4440;
CC       Q13422-7; P36009: DHR2; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-5844;
CC       Q13422-7; P39518: FAA2; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-10082;
CC       Q13422-7; P23059: MAK31; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-10950;
CC       Q13422-7; P36534: MRPL40; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-15595;
CC       Q13422-7; Q03338: PRP3; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-421;
CC       Q13422-7; P28004: PRP45; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-20640;
CC       Q13422-7; P32529: RPA12; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-15756;
CC       Q13422-7; Q04307: RPC11; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-15858;
CC       Q13422-7; P25372: TRX3; Xeno; NbExp=3; IntAct=EBI-11522367, EBI-19616;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17135265,
CC       ECO:0000269|PubMed:21548011, ECO:0000269|PubMed:22106042,
CC       ECO:0000269|PubMed:23071339}. Note=In resting lymphocytes, distributed
CC       diffusely throughout the nucleus. Localizes to pericentromeric
CC       heterochromatin in proliferating cells. This localization requires DNA
CC       binding which is regulated by phosphorylation / dephosphorylation
CC       events. {ECO:0000269|PubMed:17135265, ECO:0000269|PubMed:22106042}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Ik2]: Nucleus. Note=In resting
CC       lymphocytes, distributed diffusely throughout the nucleus. Localizes to
CC       pericentromeric heterochromatin in proliferating cells. This
CC       localization requires DNA binding which is regulated by phosphorylation
CC       / dephosphorylation events (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Ik6]: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=Ik1;
CC         IsoId=Q13422-1; Sequence=Displayed;
CC       Name=Ik2;
CC         IsoId=Q13422-2; Sequence=VSP_006848;
CC       Name=Ik3;
CC         IsoId=Q13422-3; Sequence=VSP_006850;
CC       Name=Ik4;
CC         IsoId=Q13422-4; Sequence=VSP_006847, VSP_006850;
CC       Name=Ik5;
CC         IsoId=Q13422-5; Sequence=VSP_006852;
CC       Name=Ik6;
CC         IsoId=Q13422-6; Sequence=VSP_006849;
CC       Name=Ik7;
CC         IsoId=Q13422-7; Sequence=VSP_006851;
CC       Name=Ikx;
CC         IsoId=Q13422-8; Sequence=VSP_006851, VSP_053404, VSP_053405;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in thymus, spleen and
CC       peripheral blood Leukocytes and lymph nodes. Lower expression in bone
CC       marrow and small intestine. {ECO:0000269|PubMed:8543809,
CC       ECO:0000269|PubMed:8964602}.
CC   -!- DOMAIN: The N-terminal zinc-fingers 2 and 3 are required for DNA
CC       binding as well as for targeting IKFZ1 to pericentromeric
CC       heterochromatin. {ECO:0000250}.
CC   -!- DOMAIN: The C-terminal zinc-finger domain is required for dimerization.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation controls cell-cycle progression from late G(1)
CC       stage to S stage. Hyperphosphorylated during G2/M phase.
CC       Dephosphorylated state during late G(1) phase. Phosphorylation on Thr-
CC       140 is required for DNA and pericentromeric location during mitosis.
CC       CK2 is the main kinase, in vitro. GSK3 and CDK may also contribute to
CC       phosphorylation of the C-terminal serine and threonine residues.
CC       Phosphorylation on these C-terminal residues reduces the DNA-binding
CC       ability. Phosphorylation/dephosphorylation events on Ser-13 and Ser-295
CC       regulate TDT expression during thymocyte differentiation.
CC       Dephosphorylation by protein phosphatase 1 regulates stability and
CC       pericentromeric heterochromatin location. Phosphorylated in both
CC       lymphoid and non-lymphoid tissues (By similarity). Phosphorylation at
CC       Ser-361 and Ser-364 downstream of SYK induces nuclear translocation.
CC       {ECO:0000250, ECO:0000269|PubMed:22106042,
CC       ECO:0000269|PubMed:23071339}.
CC   -!- PTM: Sumoylated. Simultaneous sumoylation on the 2 sites results in a
CC       loss of both HDAC-dependent and HDAC-independent repression. Has no
CC       effect on pericentromeric heterochromatin location. Desumoylated by
CC       SENP1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated. {ECO:0000250}.
CC   -!- DISEASE: Note=Defects in IKZF1 are frequent occurrences (28.6%) in
CC       acute lymphoblasic leukemia (ALL). Such alterations or deletions lead
CC       to poor prognosis for ALL.
CC   -!- DISEASE: Note=Chromosomal aberrations involving IKZF1 are a cause of B-
CC       cell non-Hodgkin lymphomas (B-cell NHL). Translocation t(3;7)(q27;p12),
CC       with BCL6.
CC   -!- DISEASE: Immunodeficiency, common variable, 13 (CVID13) [MIM:616873]: A
CC       primary immunodeficiency characterized by antibody deficiency,
CC       hypogammaglobulinemia, recurrent bacterial infections and an inability
CC       to mount an antibody response to antigen. CVID13 is an autosomal
CC       dominant disease associated with a striking decrease in B-cell numbers.
CC       {ECO:0000269|PubMed:21548011, ECO:0000269|PubMed:26981933}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the Ikaros C2H2-type zinc-finger protein family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/258/Ikaros";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U40462; AAC50459.1; -; mRNA.
DR   EMBL; S80876; AAB50683.1; -; mRNA.
DR   EMBL; AY377974; AAR84585.1; -; mRNA.
DR   EMBL; AK303586; BAG64603.1; -; mRNA.
DR   EMBL; BT009836; AAP88838.1; -; mRNA.
DR   EMBL; AC124014; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC233268; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471128; EAW60977.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW60978.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW60981.1; -; Genomic_DNA.
DR   EMBL; CH236955; EAL23900.1; -; Genomic_DNA.
DR   EMBL; CH471128; EAW60979.1; -; Genomic_DNA.
DR   EMBL; BC018349; AAH18349.1; -; mRNA.
DR   CCDS; CCDS59055.1; -. [Q13422-7]
DR   CCDS; CCDS69299.1; -. [Q13422-5]
DR   CCDS; CCDS75596.1; -. [Q13422-1]
DR   CCDS; CCDS78233.1; -. [Q13422-2]
DR   RefSeq; NP_001207694.1; NM_001220765.3. [Q13422-7]
DR   RefSeq; NP_001207696.1; NM_001220767.2.
DR   RefSeq; NP_001207697.1; NM_001220768.2. [Q13422-3]
DR   RefSeq; NP_001207699.1; NM_001220770.2.
DR   RefSeq; NP_001207700.1; NM_001220771.2. [Q13422-5]
DR   RefSeq; NP_001278766.1; NM_001291837.2. [Q13422-7]
DR   RefSeq; NP_001278767.1; NM_001291838.2. [Q13422-2]
DR   RefSeq; NP_001278768.1; NM_001291839.1.
DR   RefSeq; NP_001278769.1; NM_001291840.1. [Q13422-6]
DR   RefSeq; NP_001278770.1; NM_001291841.1.
DR   RefSeq; NP_001278771.1; NM_001291842.1.
DR   RefSeq; NP_001278772.1; NM_001291843.1.
DR   RefSeq; NP_001278773.1; NM_001291844.1.
DR   RefSeq; NP_006051.1; NM_006060.6. [Q13422-1]
DR   RefSeq; XP_016867157.1; XM_017011668.2. [Q13422-2]
DR   RefSeq; XP_047275681.1; XM_047419725.1. [Q13422-1]
DR   RefSeq; XP_047275682.1; XM_047419726.1. [Q13422-1]
DR   RefSeq; XP_047275689.1; XM_047419733.1. [Q13422-7]
DR   RefSeq; XP_047275690.1; XM_047419734.1. [Q13422-7]
DR   RefSeq; XP_047275701.1; XM_047419745.1. [Q13422-2]
DR   RefSeq; XP_054212979.1; XM_054357004.1. [Q13422-1]
DR   RefSeq; XP_054212987.1; XM_054357012.1. [Q13422-1]
DR   RefSeq; XP_054212988.1; XM_054357013.1. [Q13422-1]
DR   RefSeq; XP_054212992.1; XM_054357017.1. [Q13422-7]
DR   RefSeq; XP_054212996.1; XM_054357021.1. [Q13422-7]
DR   RefSeq; XP_054212997.1; XM_054357022.1. [Q13422-7]
DR   RefSeq; XP_054213010.1; XM_054357035.1. [Q13422-2]
DR   RefSeq; XP_054213011.1; XM_054357036.1. [Q13422-2]
DR   PDB; 6H0F; X-ray; 3.25 A; C/F/I/L=141-174.
DR   PDB; 8D7Z; EM; 3.10 A; C=112-196.
DR   PDB; 8D80; EM; 3.60 A; C=112-196.
DR   PDB; 8RQC; X-ray; 2.15 A; B/E=141-174.
DR   PDB; 8TNP; EM; 3.30 A; C=143-178.
DR   PDB; 8TNQ; EM; 2.41 A; C=143-178.
DR   PDB; 8TNR; EM; 2.50 A; C=143-178.
DR   PDBsum; 6H0F; -.
DR   PDBsum; 8D7Z; -.
DR   PDBsum; 8D80; -.
DR   PDBsum; 8RQC; -.
DR   PDBsum; 8TNP; -.
DR   PDBsum; 8TNQ; -.
DR   PDBsum; 8TNR; -.
DR   AlphaFoldDB; Q13422; -.
DR   EMDB; EMD-27240; -.
DR   EMDB; EMD-27241; -.
DR   EMDB; EMD-41423; -.
DR   EMDB; EMD-41424; -.
DR   EMDB; EMD-41425; -.
DR   SMR; Q13422; -.
DR   BioGRID; 115604; 309.
DR   DIP; DIP-41110N; -.
DR   ELM; Q13422; -.
DR   FunCoup; Q13422; 2318.
DR   IntAct; Q13422; 169.
DR   MINT; Q13422; -.
DR   STRING; 9606.ENSP00000331614; -.
DR   BindingDB; Q13422; -.
DR   ChEMBL; CHEMBL4739685; -.
DR   GlyCosmos; Q13422; 3 sites, 2 glycans.
DR   GlyGen; Q13422; 3 sites, 2 O-linked glycans (3 sites).
DR   iPTMnet; Q13422; -.
DR   MetOSite; Q13422; -.
DR   PhosphoSitePlus; Q13422; -.
DR   BioMuta; IKZF1; -.
DR   DMDM; 3913926; -.
DR   jPOST; Q13422; -.
DR   MassIVE; Q13422; -.
DR   PaxDb; 9606-ENSP00000331614; -.
DR   PeptideAtlas; Q13422; -.
DR   ProteomicsDB; 59401; -. [Q13422-1]
DR   ProteomicsDB; 59402; -. [Q13422-2]
DR   ProteomicsDB; 59403; -. [Q13422-3]
DR   ProteomicsDB; 59404; -. [Q13422-4]
DR   ProteomicsDB; 59405; -. [Q13422-5]
DR   ProteomicsDB; 59406; -. [Q13422-6]
DR   ProteomicsDB; 59407; -. [Q13422-7]
DR   ProteomicsDB; 66152; -.
DR   Pumba; Q13422; -.
DR   Antibodypedia; 3980; 578 antibodies from 48 providers.
DR   DNASU; 10320; -.
DR   Ensembl; ENST00000331340.8; ENSP00000331614.3; ENSG00000185811.22. [Q13422-1]
DR   Ensembl; ENST00000359197.9; ENSP00000352123.5; ENSG00000185811.22. [Q13422-7]
DR   Ensembl; ENST00000438033.5; ENSP00000396554.1; ENSG00000185811.22. [Q13422-2]
DR   Ensembl; ENST00000439701.2; ENSP00000413025.1; ENSG00000185811.22. [Q13422-7]
DR   Ensembl; ENST00000698575.1; ENSP00000513806.1; ENSG00000185811.22. [Q13422-5]
DR   GeneID; 10320; -.
DR   KEGG; hsa:10320; -.
DR   MANE-Select; ENST00000331340.8; ENSP00000331614.3; NM_006060.6; NP_006051.1.
DR   UCSC; uc003tow.5; human. [Q13422-1]
DR   AGR; HGNC:13176; -.
DR   CIViC; 10320; 1 clinical assertion and 18 evidence items across 5 molecular profiles.
DR   ClinPGx; PA37748; -.
DR   CTD; 10320; -.
DR   DisGeNET; 10320; -.
DR   GeneCards; IKZF1; -.
DR   HGNC; HGNC:13176; IKZF1.
DR   HPA; ENSG00000185811; Group enriched (bone marrow, lymphoid tissue).
DR   MalaCards; IKZF1; -.
DR   MIM; 603023; gene.
DR   MIM; 616873; phenotype.
DR   OpenTargets; ENSG00000185811; -.
DR   Orphanet; 585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2).
DR   Orphanet; 695172; Combined immunodeficiency due to dimerization defective IKAROS mutation.
DR   Orphanet; 317473; Common variable immunodeficiency phenotype due to IKAROS functional haploinsufficiency.
DR   Orphanet; 697414; Early-onset combined immunodeficiency with low Ig due to dominant negative IKAROS mutation.
DR   Orphanet; 36426; Stevens-Johnson syndrome.
DR   VEuPathDB; HostDB:ENSG00000185811; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000156782; -.
DR   HOGENOM; CLU_025502_2_0_1; -.
DR   InParanoid; Q13422; -.
DR   OMA; KAYKCEH; -.
DR   OrthoDB; 6417347at2759; -.
DR   PAN-GO; Q13422; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q13422; -.
DR   PathwayCommons; Q13422; -.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription. [Q13422-1]
DR   SignaLink; Q13422; -.
DR   SIGNOR; Q13422; -.
DR   Agora; ENSG00000185811; -.
DR   BioGRID-ORCS; 10320; 38 hits in 1187 CRISPR screens.
DR   ChiTaRS; IKZF1; human.
DR   GeneWiki; IKZF1; -.
DR   GenomeRNAi; 10320; -.
DR   Pharos; Q13422; Tbio.
DR   PRO; PR:Q13422; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q13422; protein.
DR   Bgee; ENSG00000185811; Expressed in leukocyte and 163 other cell types or tissues.
DR   ExpressionAtlas; Q13422; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005721; C:pericentric heterochromatin; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0030218; P:erythrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0030098; P:lymphocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   FunFam; 3.30.160.60:FF:000073; IKAROS family zinc finger 1; 1.
DR   FunFam; 3.30.160.60:FF:000265; IKAROS family zinc finger 1; 1.
DR   FunFam; 3.30.160.60:FF:000525; IKAROS family zinc finger 1; 1.
DR   FunFam; 3.30.160.60:FF:000080; IKAROS family zinc finger 4; 1.
DR   FunFam; 3.30.160.60:FF:000168; zinc finger protein Eos isoform X1; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 5.
DR   InterPro; IPR050589; Ikaros_C2H2-ZF.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR24404:SF36; DNA-BINDING PROTEIN IKAROS; 1.
DR   PANTHER; PTHR24404; ZINC FINGER PROTEIN; 1.
DR   Pfam; PF00096; zf-C2H2; 3.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 5.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cell cycle;
KW   Chromatin regulator; Chromosomal rearrangement; Cytoplasm;
KW   Developmental protein; Disease variant; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..519
FT                   /note="DNA-binding protein Ikaros"
FT                   /id="PRO_0000047094"
FT   ZN_FING         117..139
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         145..167
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         173..195
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         201..224
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         462..484
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         490..514
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          1..72
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          154..163
FT                   /note="Required for both high-affinity DNA binding and
FT                   pericentromeric heterochromatin localization"
FT                   /evidence="ECO:0000250"
FT   REGION          180..195
FT                   /note="Required for both high-affinity DNA binding and
FT                   pericentromeric heterochromatin localization"
FT                   /evidence="ECO:0000250"
FT   REGION          381..406
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          468..471
FT                   /note="Required for binding PP1CC"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        38..47
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            159
FT                   /note="Required for both pericentromeric heterochromatin
FT                   localization and complete DNA binding"
FT                   /evidence="ECO:0000250"
FT   SITE            162
FT                   /note="Required for both pericentromeric heterochromatin
FT                   localization and complete DNA binding"
FT                   /evidence="ECO:0000250"
FT   SITE            188
FT                   /note="Required for both pericentromeric heterochromatin
FT                   localization and DNA binding"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         13
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         23
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         63
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         101
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         140
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         168
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         196
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         258
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         261
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         289
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         295
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         298
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         361
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:23071339,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         364
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:23071339,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         389
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         391
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         398
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         402
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03267"
FT   MOD_RES         427
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   CROSSLNK        58
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        241
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         10..53
FT                   /note="Missing (in isoform Ik4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006847"
FT   VAR_SEQ         54..283
FT                   /note="Missing (in isoform Ik6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006849"
FT   VAR_SEQ         54..140
FT                   /note="Missing (in isoform Ik2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_006848"
FT   VAR_SEQ         141..283
FT                   /note="Missing (in isoform Ik5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006852"
FT   VAR_SEQ         197..283
FT                   /note="Missing (in isoform Ik3 and isoform Ik4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006850"
FT   VAR_SEQ         197..238
FT                   /note="Missing (in isoform Ik7 and isoform Ikx)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.3,
FT                   ECO:0000303|Ref.5"
FT                   /id="VSP_006851"
FT   VAR_SEQ         260..268
FT                   /note="RSLVLDRLA -> ISRAGQTSK (in isoform Ikx)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_053404"
FT   VAR_SEQ         269..519
FT                   /note="Missing (in isoform Ikx)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_053405"
FT   VARIANT         162
FT                   /note="R -> L (in CVID13; abolishes binding to DNA; has
FT                   diffuse nuclear localization; dbSNP:rs770551610)"
FT                   /evidence="ECO:0000269|PubMed:26981933"
FT                   /id="VAR_076401"
FT   VARIANT         162
FT                   /note="R -> Q (in CVID13; abolishes binding to DNA; has
FT                   diffuse nuclear localization; dbSNP:rs770551610)"
FT                   /evidence="ECO:0000269|PubMed:26981933"
FT                   /id="VAR_076402"
FT   VARIANT         167
FT                   /note="H -> R (in CVID13; abolishes binding to DNA; has
FT                   diffuse nuclear localization; dbSNP:rs869312884)"
FT                   /evidence="ECO:0000269|PubMed:26981933"
FT                   /id="VAR_076403"
FT   VARIANT         184
FT                   /note="R -> Q (in CVID13; abolishes binding to DNA; has
FT                   diffuse nuclear localization; dbSNP:rs869312885)"
FT                   /evidence="ECO:0000269|PubMed:26981933"
FT                   /id="VAR_076404"
FT   VARIANT         210
FT                   /note="Y -> C (in CVID13; decreases binding to
FT                   pericentromeric heterochromatin DNA; has diffuse nuclear
FT                   localization; dbSNP:rs869312883)"
FT                   /evidence="ECO:0000269|PubMed:21548011,
FT                   ECO:0000269|PubMed:26981933"
FT                   /id="VAR_076405"
FT   MUTAGEN         159
FT                   /note="N->A: Abolishes binding to DNA and has diffuse
FT                   nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26981933"
FT   MUTAGEN         191
FT                   /note="H->R: Abolishes binding to DNA and has diffuse
FT                   nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:26981933"
FT   CONFLICT        11..12
FT                   /note="QV -> FS (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        214
FT                   /note="S -> T (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        245
FT                   /note="N -> K (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        296
FT                   /note="Missing (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        298
FT                   /note="S -> T (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        352..355
FT                   /note="KPLA -> RRS (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        372
FT                   /note="N -> Y (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        420..426
FT                   /note="PHARNGL -> RRAQRV (in Ref. 2; AAB50683)"
FT                   /evidence="ECO:0000305"
FT   TURN            148..150
FT                   /evidence="ECO:0007829|PDB:8RQC"
FT   STRAND          153..156
FT                   /evidence="ECO:0007829|PDB:6H0F"
FT   HELIX           157..167
FT                   /evidence="ECO:0007829|PDB:8RQC"
FT   HELIX           173..176
FT                   /evidence="ECO:0007829|PDB:8TNQ"
SQ   SEQUENCE   519 AA;  57528 MW;  7B0129C4E3FE41A8 CRC64;
     MDADEGQDMS QVSGKESPPV SDTPDEGDEP MPIPEDLSTT SGGQQSSKSD RVVASNVKVE
     TQSDEENGRA CEMNGEECAE DLRMLDASGE KMNGSHRDQG SSALSGVGGI RLPNGKLKCD
     ICGIICIGPN VLMVHKRSHT GERPFQCNQC GASFTQKGNL LRHIKLHSGE KPFKCHLCNY
     ACRRRDALTG HLRTHSVGKP HKCGYCGRSY KQRSSLEEHK ERCHNYLESM GLPGTLYPVI
     KEETNHSEMA EDLCKIGSER SLVLDRLASN VAKRKSSMPQ KFLGDKGLSD TPYDSSASYE
     KENEMMKSHV MDQAINNAIN YLGAESLRPL VQTPPGGSEV VPVISPMYQL HKPLAEGTPR
     SNHSAQDSAV ENLLLLSKAK LVPSEREASP SNSCQDSTDT ESNNEEQRSG LIYLTNHIAP
     HARNGLSLKE EHRAYDLLRA ASENSQDALR VVSTSGEQMK VYKCEHCRVL FLDHVMYTIH
     MGCHGFRDPF ECNMCGYHSQ DRYEFSSHIT RGEHRFHMS
//
